Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature

Locally advanced or metastatic renal cell carcinomas (mRCCs) account for up to 15% of all kidney cancer diagnoses. Systemic therapies (with or without surgery) represent gold standard treatments, mostly based on tyrosine kinase inhibitors in association with immunotherapy. We provide an overview of...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Martina Monti, Susanna Lunardini, Igino Andrea Magli, Riccardo Campi, Giulia Primiceri, Francesco Berardinelli, Daniele Amparore, Daniela Terracciano, Giuseppe Lucarelli, Luigi Schips, Matteo Ferro, Michele Marchioni
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-05-01
Edice:	Biomedicines
Témata:	advanced renal cell carcinoma (mRCC) metastatic immunotherapy tyrosine kinase inhibitor miRNA plasmatic
On-line přístup:	https://www.mdpi.com/2227-9059/10/6/1287
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!